No abstract

Here, we also show that native GR⅐hsp90 heterocomplexes immunoadsorbed from L cell cytosol contain dynein and that GR⅐hsp90 heterocomplexes assembled in reticulocyte lysate contain cytoplasmic dynein in a manner that is competed by the PPIase domain of FKBP52.Steroid receptors move continuously into and out of the nucleus (Refs. 1-4; for review, see Ref. 5), and, depending upon the receptor, the hormone-free, untransformed receptor may have a predominantly nuclear or cytoplasmic localization. The hormone-free glucocorticoid receptor (GR) 1 is localized to the cytoplasm of most cells, and after steroid binding and transformation, it translocates to the nucleus (6 -8). Several studies with inhibitors suggest that the multiprotein hsp90-based chaperone system and the hsp90-binding immunophilin FKBP52 are involved in movement of the GR along microtubular tracks to the nucleus (for review, see Ref. 9). Assembly of receptors into heterocomplexes with hsp90 is a dynamic process (10), and it has been shown that the GR and hsp90 can move together from the cytoplasm to the nucleus (11). A couple of observations suggest that the role of hsp90 in receptor movement is likely to involve dynamic assembly and disassembly of GR⅐hsp90 heterocomplexes. For example, Yang and DeFranco (12) showed that molybdate, which binds to hsp90 and stabilizes GR⅐hsp90 heterocomplexes in vivo (13), traps the GR in the cytoplasm of cells continuously exposed to hormone. Molybdate in this case was thought to inhibit reimport of the GR into the nucleus by inhibiting the dynamic cycling of receptors into and out of their complexes with the hsp90 chaperone. Also, geldanamycin, an antibiotic that binds to the nucleotide binding site on hsp90 (14) and prevents formation of normal receptor⅐hsp90 heterocomplexes (15), impedes steroid-induced movement of the GR from the cytoplasm to the nucleus (16, 17).Some localization studies have shown the untransformed GR to colocalize with microtubules (for review, see Ref. 18), but the evidence supporting movement along microtubular tracks is indirect. Although microtubule disrupting agents, such as colcemid, do not affect the overall rate of steroid-dependent receptor translocation to the nucleus (8, 19), they eliminate the hsp90-dependent mode of receptor movement (17). Using a fusion protein of murine GR with Aequorea green fluorescent protein (GFP), we found that steroid-dependent GFP-GR translocation to the nucleus is rapid (t1 ⁄2 ϭ ϳ5 min) both in cells with intact cytoskeleton and in cells with disrupted cytoskeletal networks (17). However, in cells with normal cytoskeleton, the hsp90 inhibitor geldanamycin slowed translocation of the GFP-GR by an order of magnitude (t1 ⁄2 ϭ ϳ45 min), whereas in cells with colcemid-disrupted microtubules, geldanamycin had no effect on the translocation rate (t1 ⁄2 ϭ ϳ5 min). This suggests two mechanisms of GR movement. Under physiological conditions where the cytoskeleton is intact, diffusion is limited, and the GFP-GR utilizes a movement machinery in which the hsp90 heter...

FKBP52 is a high molecular mass immunophilin possessing peptidylprolyl isomerase (PPIase) activity that is inhibited by the immunosuppressant drug FK506. FKBP52 is a component of steroid receptor⅐hsp90 heterocomplexes, and it binds to hsp90 via a region containing three tetratricopeptide repeats (TPRs). Here we demonstrate by cross-linking of the purified proteins that there is one binding site for FKBP52/dimer of hsp90. This accounts for the common heterotetrameric structure of native receptor heterocomplexes being 1 molecule of receptor, 2 molecules of hsp90, and 1 molecule of a TPR domain protein. Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Using purified proteins, we also show that FKBP52 binds directly to the hsp90-free glucocorticoid receptor. Because neither the PPIase fragment nor the TPR fragment affects the binding of FKBP52 to the glucocorticoid receptor under conditions in which they block FKBP52 binding to dynein or hsp90, respectively, different regions of FKBP52 must determine its association with these three proteins.

FKBP52 is a steroid receptor-associated immunophilin that binds via a tetratricopeptide repeat (TPR) domain to hsp90. FKBP52 has also been shown to interact either directly or indirectly via its peptidylprolyl isomerase (PPIase) domain with cytoplasmic dynein, a motor protein involved in retrograde transport of vesicles toward the nucleus. The functional role for the PPIase domain in receptor movement was demonstrated by showing that expression of the PPIase domain fragment of FKBP52 in 3T3 cells inhibits dexamethasone-dependent nuclear translocation of a green fluorescent protein-glucocorticoid receptor chimera. Here, we show that cytoplasmic dynein is co-immunoadsorbed with two other TPR domain proteins that bind hsp90 (the cyclophilin CyP-40 and the protein phosphatase PP5). Both proteins possess PPIase homology domains, and co-immunoadsorption of cytoplasmic dynein with each is blocked by the PPIase domain fragment of FKBP52. Using purified proteins, we show that FKBP52, PP5, and the PPIase domain fragment bind directly to the intermediate chain of cytoplasmic dynein. PP5 colocalizes with both cytoplasmic dynein and microtubules, and expression of the PPIase domain fragment of FKBP52 in 3T3 cells disrupts its cytoskeletal localization. We conclude that the PPIase domains of the hsp90-binding immunophilins interact directly with cytoplasmic dynein and that this interaction with the motor protein is responsible for the microtubular localization of PP5 in vivo.

No abstract

Both plant and animal cells contain high molecular weight immunophilins that bind via tetratricopeptide repeat (TPR) domains to a TPR acceptor site on the ubiquitous and essential protein chaperone hsp90. These hsp90-binding immunophilins possess the signature peptidylprolyl isomerase (PPIase) domain, but no role for their PPIase activity in protein folding has been demonstrated. From the study of glucocorticoid receptor (GR).hsp90.immunophilin complexes in mammalian cells, there is considerable evidence that both hsp90 and the FK506-binding immunophilin FKBP52 play a role in receptor movement from the cytoplasm to the nucleus. The role of FKBP52 is to target the GR.hsp90 complex to the nucleus by binding via its PPIase domain to cytoplasmic dynein, the motor protein responsible for retrograde movement along microtubules. Here, we use rabbit cytoplasmic dynein as a surrogate for the plant homologue to show that two hsp90-binding immunophilins of wheat, wFKBP73 and wFKBP77, bind to dynein. Binding to dynein is blocked by competition with a purified FKBP52 fragment comprising its PPIase domain but is not affected by the immunosuppressant drug FK506, suggesting that the PPIase domain but not PPIase activity is involved in dynein binding. The hsp90/hsp70-based chaperone system of wheat germ lysate assembles complexes between mouse GR and wheat hsp90. These receptor heterocomplexes contain wheat FKBPs, and they bind rabbit cytoplasmic dynein in a PPIase domain-specific manner. Retention by plants of the entire heterocomplex assembly machinery for linking the GR to dynein implies a fundamental role for this process in the biology of the eukaryotic cell.

FKBPs but binds to other immunophilins termed cyclophilins (CYPs) (15). We also demonstrate that a recently described 40-kDa cyclophilin (CYP40) (16,17), known to be a component of inactivated estrogen receptor complexes (13), is a component of inactivatad GR complexes in these LMCAT cells. Immunosuppressive analogs of CsA and FK506 were studied, and we looked for a correlation between their immunosuppressive properties, their ability to inhibit peptidylprolyl isomerase (PPIase) and calcineurin (CN) phosphatase activities. Finally, we discuss the potentiation activity of these immunosuppressive drugs on the dexamethasone (Dex)-induced CAT gene expression, which may involve their direct binding to immunophilins localized in GR complexes via hsp9O. MATERIALS AND METHODSDrug Treatment of CAT Reporter Cell Line. The LMCAT cell line was established from L929 mouse fibroblast cells as described (14). They were grown in Dulbecco's modified Eagle's medium, containing 10% heat-inactivated (30 min at 55°C) fetal calf serum and 0.2 mg of geneticin (G418) per ml.Cells grown to 50% confluence were exposed to immunosuppressive drugs for 4 h followed by addition of Dex or up to 0.1% ethanol vehicle for 18 h. For hormone binding-affinity measurements, LMCAT cells were grown in 850-cm2 roller flasks.CAT enzyme activity was measured as described (14).Briefly, duplicate samples containing 3 jig of total protein were assayed by using [14C]chloramphenicol (56 mCi/mmol; 1

No abstract